Abviax's Obefazimod shows strong potential in ulcerative colitis treatment. Upcoming phase 3 trial data in Q3 2025 is a key ...

Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation ...

Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and ...

Aqilion finalizes the eosinophilic esophagitis specific formulation pharmacokinetic study with the drug candidate AQ280 Aqilion AB is pleased to announce the completion of its second Phase 1 clinical ...

Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

Key Market Trends & Drivers in 2025 One key trend is moving towards more personalized medicine through advanced biologics and small-molecule therapies. Use of targeted therapeutics such as TNF, IL, ...

Active Biotech (NASDAQ Stockholm: ACTI) today provided a status update of its development programs with laquinimod in inflammatory eye disorders and tasquinimod with the core ...

Janus kinase (JAK) inhibitors are associated with decreased mortality and fewer serious adverse events among adults hospitalized with COVID-19.

Discover a study uncovering how JAK inhibitors protect against autoimmune diabetes triggered by cancer immunotherapy.

So, the first JAK inhibitor came to market with the promise of getting oral efficacy, where previously it was injectable or infusible.

Some previous studies, including the ORAL Surveillance randomized trial, have shown moderately greater cancer risks with JAK inhibitors versus TNF inhibitors. But some other analyses of real-world ...